StockNews.com assumed coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a report released on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Adamis Pharmaceuticals Stock Down 0.8 %
Shares of ADMP stock opened at $0.12 on Friday. Adamis Pharmaceuticals has a 1-year low of $0.10 and a 1-year high of $0.62. The stock’s 50-day moving average is $0.20 and its 200 day moving average is $0.19.
Institutional Investors Weigh In On Adamis Pharmaceuticals
An institutional investor recently raised its position in Adamis Pharmaceuticals stock. State Street Corp grew its holdings in Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 475,373 shares of the specialty pharmaceutical company’s stock after acquiring an additional 55,168 shares during the quarter. State Street Corp owned 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.57% of the company’s stock.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.
- Get a free copy of the StockNews.com research report on Adamis Pharmaceuticals (ADMP)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 10 Best Consumer Discretionary ETFs
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.